With the ongoing growth of Transition Partners, now in its fifteenth year of operation, historic business relationships have broadened. In addition, new clients have joined our firm and have expanded our offerings. These relationships are summarized below.
This environmental firm designs, manufactures and sells ozone and oxygen systems for industrial applications. Specifically, its products remove hydrogen sulfide from municipal waste water. Transition Partners, Limited was engaged to raise $3 million to be used to penetrate the market for the Company’s products.
We were retained by this developer of patented advanced enabling materials technology for various industrial applications to procure nearly $5 million in staged, incremental financing from key strategic financing sources. We assisted the Company in restructuring its business and helped convert certain debt to equity.
This provider of state-of-the-art voice interactive on-board navigational products retained Transition Partners to procure working capital for the commercial launch of its products. In addition, the Company requested the services of Transition Partners to facilitate alliances with Fortune 500 organizations for the firm to accelerate the commercial reach of the Company’s products.
This integrator of wide area surveillance and high technology homeland security systems retained our firm through its publicly-held parent corporation, Pure Technologies, Limited, to explore strategic alternatives. To this end, we facilitated the sale of this subsidiary firm to a homeland security services company, ICX Technologies, Limited.
This speciality, technology-based manufacturing company serving various Fortune 500 clients retained our firm. We were asked to evaluate strategic alternatives including procuring up to $3 million of new capital for the business. As a result, investment sources were identified and term sheets procured for this financing.
This innovator of herbal pharmaceutical preparations requested Transition Partners, Limited to commence a financing for the purpose of the Company’s commencement of clinical trials to validate its herbal products and their physiological results. Various investment sources were identified and important dialogues initiated.
